PharmaCyte Biotech Inc
PMCB
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.88M
Close$
$2.07
166.6% upside
Current Fair Value
166.6% upsideUndervalued by 166.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.88 Million |
|---|---|
| Enterprise Value | $-15,287,524.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $3.19 |
| Beta | 0.52 |
| Outstanding Shares | 9,262,829 |
Return
| Return on Equity | -10.98% |
|---|---|
| Return on Assets | -7.66% |
| Return on Invested Capital | -23.80% |
Valuation & Multiples
| P/E Ratio | -2.03 |
|---|---|
| PEG | 1.63 |
| Price to Sales | - |
| Price to Book Ratio | 0.19 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.19 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 17, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 1, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 160,200▼ 13.92% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.44%▼ 4.03% |
|---|---|
| Total Invested | $643,180▼ 9.66% |
| Investors Holding | 33▲ 6.00% |
ESG Score
No data
About PharmaCyte Biotech Inc
4 employeesPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being use...